Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CYP2D6 INHIBITION IN PATIENTS TREATED WITH SERTRALINE
Autore:
SPROULE BA; OTTON SV; CHEUNG SW; ZHONG XH; ROMACH MK; SELLERS EM;
Indirizzi:
ADDICT RES FDN,33 RUSSELL ST TORONTO ON M5S 2S1 CANADA ADDICT RES FDN TORONTO ON M5S 2S1 CANADA UNIV TORONTO,DEPT PHARMACOL TORONTO ON M5S 1A1 CANADA UNIV TORONTO,DEPT MED TORONTO ON M5S 1A1 CANADA UNIV TORONTO,DEPT PSYCHIAT TORONTO ON M5S 1A1 CANADA UNIV TORONTO,FAC PHARM TORONTO ON M5S 1A1 CANADA
Titolo Testata:
Journal of clinical psychopharmacology
fascicolo: 2, volume: 17, anno: 1997,
pagine: 102 - 106
SICI:
0271-0749(1997)17:2<102:CIIPTW>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
OBSESSIVE-COMPULSIVE-DISORDER; HYDROXYLATION IN-VITRO; TRICYCLIC ANTIDEPRESSANTS; POOR METABOLIZERS; HUMAN-LIVER; FLUOXETINE; DESIPRAMINE; CYTOCHROME-P4502D6; DEBRISOQUINE; PAROXETINE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
24
Recensione:
Indirizzi per estratti:
Citazione:
B.A. Sproule et al., "CYP2D6 INHIBITION IN PATIENTS TREATED WITH SERTRALINE", Journal of clinical psychopharmacology, 17(2), 1997, pp. 102-106

Abstract

Sertraline, a selective serotonin reuptake inhibitor used to treat depression, inhibits CYP2D6 in vitro (Ki = 1.2 mu M) less potently than fluoxetine (Ki = 0.15 mu M). To determine the extent and time course of CYP2D6 inhibition in patients, six males (mean age: 40 years, range:29-64 years), who were starting treatment for depression with sertraline, were phenotyped on five occasions (once before treatment and approximately 3, 7, 14, and 21 days later). Phenotype status was determined using oral dextromethorphan (30 mg) by calculating the urinary ratioof O-demethylated metabolites to parent drug (i.e., log ODMR). CYP2D6genotype was determined by leukocyte DNA analysis using polymerase chain reaction amplification. Compliance was confirmed by sertraline plasma levels. Daily sertraline dosages ranged from 50 to 150 mg. Genotype results indicated all subjects were extensive metabolizers (four homozygous wild type [wt], two heterozygous wt/B mutation). Phenotype results showed that CYP2D6 inhibition in patients treated with sertralineappeared to be related to baseline CYP2D6 activity and sertraline dosage. Some patients with high CYP2D6 activity can demonstrate inhibition with sertraline dosages as low as 50 mg.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/01/20 alle ore 21:03:59